Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and
rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more
scientific basis for clinical decision-making.